Progression from unilateral to bilateral parkinsonism in early Parkinson disease: Implication of mesocortical dopamine dysfunction by PET

Journal of Nuclear Medicine

Volumn 51, Issue 8, 2010, Pages 1250-1257

  Yagi, Shunsuke ^a   Yoshikawa, Etsuji ^b   Futatsubashi, Masami ^b   Yokokura, Masamichi ^a   Yoshihara, Yujiro ^a   Torizuka, Tatsuo ^a   Ouchi, Yasuomi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CENTRAL RESEARCH LABORATORY   (Japan)

Author keywords

11C CFT; Mesocortical dopamine function; Parkinson disease; Positron emission tomography; Unilateral parkinsonism

Indexed keywords

2BETA CARBOMETHOXY 3BETA (4 FLUOROPHENYL)TROPANE C 11; ANTIPARKINSON AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE UPTAKE INHIBITOR; LEVODOPA; SELEGILINE; TRACER; UNCLASSIFIED DRUG; (1R (EXO,EXO)) 3 (4 FLUOROPHENYL) 8 METHYL 8 AZABICYCLO(3.2.1)OCTANE 2 CARBOXYLIC ACID, METHYL ESTER; (1R-(EXO,EXO))-3-(4-FLUOROPHENYL)-8-METHYL-8- AZABICYCLO(3.2.1)OCTANE-2-CARBOXYLIC ACID, METHYL ESTER; COCAINE; DIAGNOSTIC AGENT; DOPAMINE TRANSPORTER; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BRAIN CORTEX; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; FEMALE; FOLLOW UP; HUMAN; IN VIVO STUDY; INFORMATION PROCESSING; MALE; NEOSTRIATUM; NIGRONEOSTRIATAL SYSTEM; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEUS ACCUMBENS; ORBITAL CORTEX; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PUTAMEN; RATING SCALE; DISEASE COURSE; HEMISPHERIC DOMINANCE; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGY; REGRESSION ANALYSIS; SCINTISCANNING;

ADULT; AGED; CEREBRAL CORTEX; COCAINE; DISEASE PROGRESSION; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FUNCTIONAL LATERALITY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REGRESSION ANALYSIS;

EID: 77956211243     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.076802     Document Type: Article

References (40)

1. German DC, Manaye K, Smith W, Woodward D, Saper C. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol. 1989;26:507-514. (Pubitemid 19247226)
2. McGeer PL, Itagaki S, Akiyama H, McGeer E. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol. 1988;24:574-576.
3. 123I]b-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology. 2001;57:2089-2094.
4. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F18 activity. Arch Neurol. 2005;62:378-382. (Pubitemid 40349472)
5. Ouchi Y, Yoshikawa E, Okada H, et al. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for β-CFT binding with positron emission tomography. Ann Neurol. 1999;45:601-610. (Pubitemid 29217588)
6. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol. 1993;34:423-431.
7. Frey KA, Koeppe R, Kilbourn M, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol. 1996;40:873-884.
8. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114:2283-2301.
9. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998;64:314-319. (Pubitemid 28159833)
10. Bezard E, Dovero S, Prunier C, et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci. 2001;21:6853-6861.
11. Ouchi Y, Nobezawa S, Okada H, Yoshikawa E, Futatsubashi M, Kaneko M. Altered glucose metabolism in the hippocampal head in memory impairment. Neurology. 1998;51:136-142.
12. Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol. 2005;57:168-175.
13. Mai J, Assheuer J, Paxinos G. Atlas of the Human Brain. New York, NY: Academic Press; 1997.
14. Ouchi Y, Okada H, Yoshikawa E, Nobezawa S, Futatsubash M. Brain activation during maintenance of standing postures in humans. Brain. 1999;122:329-338.
15. Watanabe M, Shimizu K, Omura T, et al. A new high-resolution PET scanner dedicated to brain research. IEEE Trans Nucl Sci. 2002;49:634-639.
16. 11C] beta-CFT is reduced in Alzheimer's disease assessed by positron emission tomography. Neurology. 1998;50:152-156.
17. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
18. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism: a prospective study. Can J Neurol Sci. 1991;18:275-278.
19. Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson disease. Arch Neurol. 2000;57:369-372.
20. Marek K, Jennings D, Tamagnan G, Seibyl J. Biomarkers for Parkinson's disease: tools to assess Parkinson's disease onset and progression. Ann Neurol. 2008;64:S111-S121.
21. 18F] CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease. Synapse. 2001;40:193-200.
22. 11C]WIN 35,428. Synapse. 1993;15:130-142.
23. 11C]-CFT and PET in a primate model of parkinsonism. Neuroreport. 1992;3:265-268.
24. Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci. 1996;16:436-447.
25. 99mTc] TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med. 2000;41:584-589.
26. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain. 2009;132:2970-2979.
27. Martin WR, Wieler M, Stoessl A, Schulzer M. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann Neurol. 2008;63:388-394.
28. Szabo J. Organization of the ascending striatal afferents in monkeys. J Comp Neurol. 1980;189:307-321. (Pubitemid 10181918)
29. 123I-FP-CIT SPECT striatal uptake. Mov Disord. 2000;15:692-698.
30. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197-211.
31. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet. 2009;373:2055-2066.
32. 123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology. 1996;46:231-237.
33. Lieberman A. Depression in Parkinson's disease: a review. Acta Neurol Scand. 2006;113:1-8.
34. Wise RA. Roles for nigrostriatal-not just mesocorticolimbic-dopamine in reward and addiction. Trends Neurosci. 2009;32:517-524.
35. Ito H Takahashi H, Arakawa R, Takano H, Suhara T. Normal database of dopaminergic neurotransmission system in human brain measured by positron emission tomography. Neuroimage. 2008;39:555-565.
36. Vingerhoets FJ, Schulzer M, Calne D, Snow B.Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol. 1997;41:58-64.
37. Pahwa R, Factor SA, Lyons KE, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review)- report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983-995.
38. Jubault T, Monetta L, Straffella AP, et al. L-dopa medication in Parkinson's disease restores activity in the motor cortico-striatal loop but does not modify the cognitive network. PLoS ONE. 2009;4:e6154.
39. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287:1653-1661.
40. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology. 2005;64:208-215.